Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
1.
Expert Rev Anti Infect Ther ; 10(8): 869-73, 2012 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-23030326

RESUMEN

Over a period of 14 years, the authors have studied thioridazine, an old neuroleptic, that has been shown to have in vitro activity against intracellular Mycobacterium tuberculosis, regardless of its antibiotic resistance status, thioridazine cures infected mice of antibiotic-susceptible and multidrug-resistant tuberculosis (TB) infections and, when used in combination with antibiotics used for therapy of TB, renders the organism significantly more susceptible. This article will describe the authors' further work and the mechanisms by which thioridazine alone and in combination with antibiotics cures an extensively drug-resistant infection and why it is expected to cure totally drug-resistant TB infections as well. The concepts presented are entirely new and because they focus on the activation of killing by nonkilling macrophages where M. tuberculosis normally resides during infection, and coupled to the inhibition of efflux pumps which contribute to the antibiotic-resistant status, effective therapy of any antibiotic-resistant TB infection is possible.


Asunto(s)
Antibióticos Antituberculosos/uso terapéutico , Tuberculosis Extensivamente Resistente a Drogas/tratamiento farmacológico , Mycobacterium tuberculosis/patogenicidad , Tioridazina/uso terapéutico , Animales , Clorpromazina/farmacología , Evaluación de Medicamentos , Farmacorresistencia Bacteriana Múltiple , Quimioterapia Combinada/métodos , Tuberculosis Extensivamente Resistente a Drogas/microbiología , Humanos , Macrófagos/efectos de los fármacos , Macrófagos/microbiología , Ratones , Pruebas de Sensibilidad Microbiana , Mycobacterium tuberculosis/efectos de los fármacos , Prevalencia
2.
In Vivo ; 26(2): 223-9, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-22351662

RESUMEN

AIM: To evaluate a new series of 16 hydantoin derivatives for activity against the intrinsic and overexpressed efflux pumps of the ATTC 25923 Staphylococcus aureus and the clinical Staphylococcus aureus HPV-107 strain, respectively. MATERIALS AND METHODS: The hydantoin compounds were evaluated for activity against the efflux pumps of the ATTC 25923 S. aureus and the clinical S. aureus HPV-107 strains by the aid of the automated ethidium bromide method. Compounds that inhibited the efflux pumps of either strain were evaluated for ability to reduce or reverse resistance of these strains to oxacillin. RESULTS: Although most of the hydantoins inhibited the efflux pumps of the ATTC strain, none reduced the resistance of this strain to oxacillin. In contrast, the inhibition of the Qac efflux pump present in HPV-107 was inhibited to some degree, by much higher concentrations of the hydantoin compounds than that needed for similar activity against the ATTC strain; only hydantoin PI8a significantly reduced the minimum inhibitory concentration of oxacillin against the HPV-107 strain. CONCLUSION: Hydantoin compound PI8a may have potential for therapy of a methicillin-resistant S. aureus infection whose multidrug-resistant phenotype is due to overexpression of an efflux pump.


Asunto(s)
Proteínas Bacterianas/antagonistas & inhibidores , Transporte Biológico/efectos de los fármacos , Farmacorresistencia Bacteriana Múltiple/efectos de los fármacos , Hidantoínas/farmacología , Oxacilina/farmacología , Staphylococcus aureus/efectos de los fármacos , Proteínas Bacterianas/metabolismo , Sistemas de Computación , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos , Etidio/metabolismo , Colorantes Fluorescentes/metabolismo , Proteínas de Transporte de Membrana/metabolismo , Staphylococcus aureus Resistente a Meticilina/efectos de los fármacos , Staphylococcus aureus Resistente a Meticilina/metabolismo , Pruebas de Sensibilidad Microbiana , Estructura Molecular , Oxacilina/metabolismo , Resistencia a las Penicilinas/efectos de los fármacos , Plásmidos/genética , Staphylococcus aureus/metabolismo
3.
In Vivo ; 26(2): 293-7, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-22351672

RESUMEN

BACKGROUND: Multidrug resistance (MDR) is one of the major concerns in the treatment of cancer and one of the major causes of therapy failure. The overexpression of an ABC transporter, the ABCB1, is often associated with MDR in cancer. Previously it was observed that hydantoin compounds can modulate the activity of the ABCB1 pump. MATERIALS AND METHODS: Fourteen hydantoin derivatives were synthesized and studied for their capacity to increase accumulation of ethidium bromide (EB) by mouse lymphoma cancer cells that were transfected with the human ABCB1 gene and overexpress the human ABCB1 pump. RESULTS: It was observed that the accumulation of EB by the cells in the presence of four of the newly synthesized hydantoins was strongly increased. Similar but milder effects were also observed for the other seven hydantoins; the remaining three had no activity. CONCLUSION: The 14 hydantoin compounds studied belong to three different structural groups. Structure-activity relationships were studied and important molecular substituents that were possibly responsible for increased the activity of the molecules were identified. This important information may lead to the continuation of our work and to the future synthesis of more active compounds.


Asunto(s)
Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/antagonistas & inhibidores , Hidantoínas/farmacología , Subfamilia B de Transportador de Casetes de Unión a ATP , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/genética , Animales , Línea Celular Tumoral/efectos de los fármacos , Evaluación Preclínica de Medicamentos , Resistencia a Múltiples Medicamentos/efectos de los fármacos , Etidio/análisis , Etidio/metabolismo , Colorantes Fluorescentes/análisis , Colorantes Fluorescentes/metabolismo , Humanos , Hidantoínas/síntesis química , Hidantoínas/química , Transporte Iónico/efectos de los fármacos , Leucemia L5178/patología , Ratones , Estructura Molecular , Relación Estructura-Actividad , Transfección
4.
Phytother Res ; 24(5): 782-6, 2010 May.
Artículo en Inglés | MEDLINE | ID: mdl-19827025

RESUMEN

The role of quorum sensing (QS) is well known in microbial pathogenicity and antibiotic resistance. QS is responsible for motility, swarming, and biofilm production based on the signal molecules, e.g., acylated homoserine lactones (AHLs) produced by micro-organisms above certain population density. The inhibition of QS may reduce pathogenicity, antibiotic resistance and biofilm formation in systemic and local infections. The homoserine lactones and other transmitters contribute to antibiotic resistance and pathogenicity of several bacteria; consequently the inhibition of QS signals reduces the problem of resistance and virulence. Due to the increasing number of persistent non-treatable infections, there is an urgent need to develop new strategies to combat infections that destabilize bacterial communities in the host. The effect of essential oils on bacterial growth and QS were evaluated using the sensor strain Chromobacterium violaceum CV026 and N-acyl homoserine lactone (AHL) producing Escherichia coli ATTC 31298 and the grapevine colonizing Ezf 10-17 strains. Of the tested oils, rose, geranium, lavender and rosemary oils were the most potent QS inhibitors. Eucalyptus and citrus oils moderately reduced pigment production by CV026, whereas the chamomile, orange and juniper oils were ineffective.


Asunto(s)
Antibacterianos/farmacología , Aceites Volátiles/farmacología , Aceites de Plantas/farmacología , Percepción de Quorum/efectos de los fármacos , Acil-Butirolactonas/metabolismo , Chromobacterium/efectos de los fármacos , Chromobacterium/crecimiento & desarrollo , Escherichia coli/efectos de los fármacos , Escherichia coli/crecimiento & desarrollo , Magnoliopsida/química , Rosmarinus
5.
Int J Antimicrob Agents ; 30(3): 242-9, 2007 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-17644318

RESUMEN

Diclofenac sodium (Dc), an anti-inflammatory agent, has remarkable inhibitory action both against drug-sensitive and drug-resistant clinical isolates of various Gram-positive and Gram-negative bacteria. The aim of this study was to determine the ability of Dc to protect mice from a virulent Salmonella infection. Dc injected at 1.5 microg/g and 3.0 microg/g mouse body weight significantly protected animals from the lethality of Salmonella infection. As was the case for the in vitro interaction, Dc in combination with streptomycin was even more effective. The non-antibiotic drug Dc has potential for the management of problematic antibiotic-resistant bacterial infections.


Asunto(s)
Antiinflamatorios no Esteroideos/uso terapéutico , Infecciones Bacterianas/tratamiento farmacológico , Infecciones Bacterianas/microbiología , Diclofenaco/uso terapéutico , Farmacorresistencia Bacteriana , Animales , Antibacterianos/farmacología , Antiinflamatorios no Esteroideos/toxicidad , Antipsicóticos/farmacología , Recuento de Colonia Microbiana , Medios de Cultivo , ADN Bacteriano/genética , ADN Bacteriano/aislamiento & purificación , Diclofenaco/toxicidad , Sinergismo Farmacológico , Escherichia coli/efectos de los fármacos , Infecciones por Escherichia coli/tratamiento farmacológico , Infecciones por Escherichia coli/microbiología , Masculino , Ratones , Pruebas de Sensibilidad Microbiana , Plásmidos/genética , Salmonella enterica/efectos de los fármacos , Infecciones Estafilocócicas/tratamiento farmacológico , Infecciones Estafilocócicas/microbiología , Staphylococcus aureus/efectos de los fármacos , Estreptomicina/farmacología , Trifluoperazina/farmacología
6.
Phytother Res ; 21(7): 601-4, 2007 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-17357175

RESUMEN

Ergosterol peroxide, cycloart-23-en-3beta,25-diol, vanillin and 4-hydroxybenzaldehyde have been isolated and characterized from a crude methanol extract of Euphorbia lagascae. Previous studies have shown contradictory results about the antibacterial activity of ergosterol peroxide against Mycobacterium tuberculosis. In order to clarify this question, the activity of this compound was tested against Mycobacterium tuberculosis H37Rv ATCC 27294 strain using two different systems: BACTEC 460TB (Bactec 460) and BACTEC MGIT 960 system (Bactec 960). The results obtained show that significant activity was demonstrable only with the Bactec 460 system. The lack of activity noted with the Bactec 960 system appears to be due to the much faster growth rate of the organism in the medium of this system as opposed to that of the Bactec 460 system. Ergosterol peroxide is also shown by the current study to be devoid of any activity against an antibiotic sensitive ATCC strain of Staphylococcus aureus.


Asunto(s)
Antituberculosos/farmacología , Ergosterol/análogos & derivados , Euphorbia , Mycobacterium tuberculosis/efectos de los fármacos , Fitoterapia , Antituberculosos/administración & dosificación , Antituberculosos/uso terapéutico , Resistencia a Múltiples Medicamentos , Ergosterol/administración & dosificación , Ergosterol/farmacología , Ergosterol/uso terapéutico , Humanos , Pruebas de Sensibilidad Microbiana , Mycobacterium tuberculosis/clasificación , Extractos Vegetales/administración & dosificación , Extractos Vegetales/farmacología , Extractos Vegetales/uso terapéutico , Tuberculosis Resistente a Múltiples Medicamentos/tratamiento farmacológico
7.
Curr Drug Targets ; 7(7): 887-91, 2006 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-16842219

RESUMEN

The antibiotic resistance is now common place throughout the globe. Two highly problematic antibiotic resistant infections are those produced by multi-drug resistant Mycobacterium tuberculosis (MDRTB) and methicillin resistant Staphylococcus aureus (MRSA). Although vancomycin is useful for therapy of MRSA, there is now evidence that resistance to this antibiotic is taking place. Intracellular infections of MRSA are very difficult to manage and are recurrent especially when invasive prosthetic devices are employed. This mini-review provides cogent evidence that both intracellular MDRTB and intracellular MRSA can be killed by concentrations of the non-antibiotic phenothiazine, Thioridazine, at concentrations in the medium that are below those present in the plasma of patients treated with this agent. Although thioridazine has been claimed to cause arrhythmias and even sudden death, the frequencies of these episodes are rare and when present, they are related to the patients underlying cardiac status as opposed to the direct effect of the agent itself. The authors do not suggest that thioridazine be used indiscriminately for MDRTB or intracellular infections produced by MRSA. However, there are circumstances where there are no alternative forms of therapy and the patient faces an unfavourable prognosis. For these highly selective and controlled situations, the use of thioridazine in the manner employed for the therapy of psychosis is recommended (compassionate therapy).


Asunto(s)
Resistencia a la Meticilina , Infecciones Estafilocócicas/tratamiento farmacológico , Staphylococcus aureus/efectos de los fármacos , Tioridazina/uso terapéutico , Tuberculosis Resistente a Múltiples Medicamentos/tratamiento farmacológico , Países en Desarrollo , Humanos , Resistencia a la Vancomicina
8.
In Vivo ; 19(4): 733-6, 2005.
Artículo en Inglés | MEDLINE | ID: mdl-15999542

RESUMEN

Patients presenting with Acquired Immune Deficiency Syndrome (AIDS) are predisposed to co-infection with Mycobacterium avium. The management of such patients is problematic due to underlying immuno-incompetence and the high resistance of M. avium to most non-toxic compounds. Therefore, the need for effective agents is obvious. Because phenothiazines, especially the relatively mild thioridazine, have significant activity against Mycobacterium tuberculosis, we investigated the in vitro activity of chlorpromazine, thioridazine, promazine, promethazine and desipramine against a reference and clinical strains of M. avium. The results obtained show that whereas all of the phenothiazines employed in this study had an minimum inhibitory concentration (MIC) against the strains studied that ranged from ca. 10 to > 50 mg/L, as was previously shown for M. tuberculosis, thioridazine was the most active of the group against M. avium.


Asunto(s)
Infecciones Oportunistas Relacionadas con el SIDA/tratamiento farmacológico , Antipsicóticos/farmacología , Complejo Mycobacterium avium/efectos de los fármacos , Fenotiazinas/farmacología , Tioridazina , Antipsicóticos/uso terapéutico , Relación Dosis-Respuesta a Droga , Humanos , Pruebas de Sensibilidad Microbiana , Complejo Mycobacterium avium/crecimiento & desarrollo , Infección por Mycobacterium avium-intracellulare , Fenotiazinas/uso terapéutico , Tioridazina/farmacología , Tioridazina/uso terapéutico
10.
Phytother Res ; 17(5): 512-9, 2003 May.
Artículo en Inglés | MEDLINE | ID: mdl-12748989

RESUMEN

Although alkaloids from the family Aizoaceae have anticancer activity, species of this family have received little attention. Because these alkaloids also exhibit properties normally associated with compounds that have activity at the level of the plasma membrane, a methanol extract of Carpobrotus edulis, a common plant found along the Portuguese coast, was studied for properties normally associated with plasma membrane active compounds. The results of this study show that the extract is non-toxic at concentrations that inhibit a verapamil sensitive efflux pump of L5178 mouse T cell lymphoma cell line thereby rendering these multi-drug resistant cells susceptible to anticancer drugs. These non-toxic concentrations also prime THP-1 human monocyte-derived macrophages to kill ingested Staphylococcus aureus and to promote the release of lymphokines associated with cellular immune functions. The extract also induces the proliferation of THP-1 cells within 1 day of exposure to quantities normally associated with phytohaemagglutinin. The potential role of the compound(s) isolated from this plant in cancer biology is intriguing and is currently under investigation. It is supposed that the resistance modifier and immunomodulatory effect of this plant extract can be exploited in the experimental chemotherapy of cancer and bacterial or viral infections.


Asunto(s)
Aizoaceae , Extractos Vegetales/farmacología , Staphylococcus aureus/efectos de los fármacos , Animales , Antibacterianos/farmacología , Modulación Antigénica/efectos de los fármacos , Antineoplásicos Fitogénicos/farmacología , División Celular/efectos de los fármacos , Línea Celular , Resistencia a Múltiples Medicamentos , Humanos , Macrófagos/efectos de los fármacos , Ratones , Células Tumorales Cultivadas/efectos de los fármacos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA